WuXia293

武侠293

Stable

稳定的

platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.

该平台通过消除或显著减轻难以表达分子中的截短现象，展示了高滴度、人类糖基化和改进的产品质量。

WuXia293

武侠293

Stable

稳定的

platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing.

平台在长期细胞传代过程中保持稳定的表达和一致的产品质量，从而实现可扩展的临床和商业生产。

SHANGHAI

上海

,

，

Aug. 11, 2025

2025年8月11日

/PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293

/PRNewswire/ -- 全球领先的合同研究、开发和生产组织（CRDMO）药明生物（2269.HK）今日宣布推出WuXia293

Stable

稳定

, a new platform designed for the development and manufacturing of innovative, difficult-to-express molecules that are stably expressed in HEK293 cells. The platform, which demonstrates high titers, robust stability and superior quality, significantly enhances the developability and manufacturability of these molecules, offering a highly efficient CMC solution for biologics that are sophisticated in both structure and function..

，一个专为开发和制造创新、难以表达且在HEK293细胞中稳定表达的分子而设计的新平台。该平台展示了高滴度、强大的稳定性和卓越的质量，显著增强了这些分子的可开发性和可制造性，为结构和功能复杂的生物制品提供了高效的CMC解决方案。

Conventionally, CHO cells have been widely utilized for recombinant protein expression with proven track record of high titers, and good developability and manufacturability. However, complex modalities may not be compatible with CHO expression system, resulting in low titer levels and truncation issues, due to the impact of some CHO-specific host cell proteins (HCPs), that compromise the quality and functionality of the protein products.

传统上，CHO细胞已被广泛用于重组蛋白表达，并有着高滴度、良好的开发性和可制造性的可靠记录。然而，由于某些CHO特异性宿主细胞蛋白（HCP）的影响，复杂模式可能与CHO表达系统不兼容，导致滴度水平低和截短问题，从而影响蛋白质产品的质量和功能。

In contrast, HEK293 cells can eliminate or significantly alleviate truncation issues in expressing complex molecules while maintaining high titer levels..

相比之下，HEK293细胞在表达复杂分子时可以消除或显著减轻截短问题，同时保持高滴度水平。

WuXi Biologics developed WuXia293

药明生物开发了WuXia293

Stable

稳定的

by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293

通过利用其专有的HEK293细胞系。WuXia293源自药明生物经过严格验证的哺乳动物细胞系开发平台家族WuXia™。

Stable

稳定

demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism.

展示了与WuXia™相当的生产力、质量和稳定性，同时与其工艺保持完全兼容，这由其强劲的增长和均衡的代谢得以证明。

The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293

该平台可将单克隆抗体的补料分批滴度提升至高达 5.0 克/升，同时大幅提高纯度。WuXia293

Stable

稳定的

offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages. Furthermore, the WuXia293

提供了灵活可扩展的培养规模，以满足不同研究和临床前开发阶段的多样化需求。此外，WuXia293

Stable

稳定

cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293

细胞系在长期的细胞传代过程中保持稳定的表达和一致的质量，能够实现2000L规模的补料分批和1000L规模的灌流的可扩展的临床和商业生产。此外，药明生物还为WuXia293提供全面的服务套件。

Stable

稳定

platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution.

平台，包括作为其一站式CMC解决方案的一部分的细胞库测试和病毒清除验证。

The launch of the WuXia293

吴霞293的发布

Stable

稳定

platform has further strengthened the service capabilities of WuXi Biologics' WuXia™ platform family. Besides WuXia293

该平台进一步增强了药明生物 WuXia™ 平台系列的服务能力。除了 WuXia293 之外

stable

稳定的

, the WuXia™ platform has already derived multiple cell line development platforms, including WuXia

，WuXia™ 平台已经衍生出多个细胞系开发平台，包括 WuXia

ADCC

抗体依赖性细胞介导的细胞毒性作用

Plus™ and WuXia RidGS™, to address customers' diverse requirements.

Plus™ 和 WuXia RidGS™，以满足客户的不同需求。

Dr.

博士

Chris Chen

陈克里斯

, CEO of WuXi Biologics

药明生物首席执行官

, commented, 'We are excited to launch an industry-leading solution that significantly enhances the development of advanced therapeutics. WuXia293

，评论道，“我们很高兴推出一个行业领先的解决方案，该方案显著增强了先进治疗药物的开发。WuXia293

Stable

稳定

stands as a powerful testament to WuXi Biologics' unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry. Once again we are reaffirming our promise to enable our clients in accelerating the delivery of innovative biologics to patients worldwide.

有力地证明了药明生物对“让每一个生物药都能生产”的愿景的坚定承诺，体现了我们对技术创新的奉献精神，使我们能够灵活应对生物制药行业不断变化的需求。我们再次重申我们的承诺，帮助客户加快将创新生物药带给全球患者的步伐。

'.

‘。

About the WuXia™ Cell Line Development Platform Family

关于WuXia™细胞系开发平台家族

WuXia™ is a proven, high-yield (up to about 11 g/L) mammalian cell line platform family developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia™ platform family have generated over 1000 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing as of 2024..

WuXia™ 是由药明生物开发的一种经过验证的高产量（高达约 11 g/L）哺乳动物细胞系平台家族。截至 2024 年，WuXia™ 平台家族已生成超过 1000 种细胞系，用于表达单克隆抗体、双特异性抗体、融合蛋白、酶和其他重组蛋白，并已被全球监管机构接受用于临床和商业化生产。

The WuXia™ platform family include WuXia

武侠™平台家族包括武侠

ADCC

抗体依赖性细胞介导的细胞毒性作用

Plus™ for developing and manufacturing afucosylated antibodies to elicit an enhanced ADCC response, WuXia RidGS™ for non-antibiotic cell line development, and the latest WuXia293

Plus™用于开发和生产去岩藻糖基化的抗体，以引发增强的ADCC反应，WuXia RidGS™用于非抗生素细胞系开发，以及最新的WuXia293。

Stable

稳定的

for expressing difficult-to-express molecules built on HEK293 cell lines. The WuXia™ cell line development platform family continue to expand to cater to the diverse needs of global customers.

用于表达基于HEK293细胞系的难以表达的分子。WuXia™ 细胞系开发平台家族不断扩大，以满足全球客户的多样化需求。

SOURCE WuXi Biologics

来源：药明生物

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用